A close relationship links metabolic fatty liver disease to chronic kidney disease. This liver condition, formerly known as non-alcoholic fatty liver disease, now affects nearly one-third of adults worldwide. It is characterized by an abnormal accumulation of fat in the liver, often associated with metabolic disorders such as obesity, type 2 diabetes, or hypertension. Its impact is not limited to the liver: it is now recognized as a multisystemic disease, affecting the heart and kidneys in particular.<\/p>\n
A thorough analysis of twenty studies conducted up to June 2025 confirms this link. Researchers examined data from adult populations without initial kidney failure, comparing individuals with fatty liver disease to those without. The results reveal that the risk of developing chronic kidney disease is significantly higher in affected individuals. Specifically, this risk increases by 25% for those suffering from the most studied form of the disease, and by 29% for those with a version associated with marked metabolic dysfunctions. Even with new medical definitions, the risk remains increased by 16%.<\/p>\n
This association is explained by several mechanisms. The liver, far from being a mere victim of fat accumulation, plays an active role in the deterioration of other organs. It produces inflammatory substances and molecules that worsen insulin resistance, a key factor in the development of kidney damage. Additionally, the excess fat in the blood, often observed in these patients, promotes oxidative stress and the production of compounds toxic to the kidneys. These processes contribute to altering the structure and function of the small blood vessels in the kidney, gradually leading to kidney failure.<\/p>\n
Metabolic fatty liver disease does not merely increase the risk of hepatic complications such as cirrhosis or cancer. It is part of a vicious cycle where metabolic disorders perpetuate and worsen kidney damage. For example, obesity alters blood circulation in the kidneys and reduces the density of filtering cells, accelerating their wear. Similarly, insulin resistance, common in these patients, promotes fibrosis and inflammation, two phenomena that damage kidney tissue.<\/p>\n
The studies included in this analysis used rigorous methods to diagnose liver disease, such as abdominal ultrasound or biopsy. These techniques allow for the precise detection of fat in the liver and rule out other causes of liver damage, such as excessive alcohol consumption. The researchers also ensured to exclude participants already suffering from kidney failure at the start of the studies, to measure only the occurrence of new cases.<\/p>\n
The results obtained are robust. Even after adjusting the data to account for factors such as age, sex, smoking, or the presence of diabetes, the link between fatty liver disease and kidney failure persists. This suggests that this association is not simply due to shared risk factors, but rather to direct biological mechanisms. The authors emphasize, however, that further research is needed to fully understand these processes and identify precise therapeutic targets.<\/p>\n
Awareness of this relationship is crucial for healthcare professionals. Indeed, metabolic fatty liver disease is a preventable and treatable condition. Simple measures, such as a balanced diet, regular physical activity, or weight management, can significantly reduce its impact. Additionally, new obesity medications, such as GLP-1 receptor agonists, offer promising prospects for its treatment. These therapies, by promoting significant weight loss, also improve metabolic parameters and could thus protect the kidneys.<\/p>\n
In conclusion, this analysis confirms that metabolic fatty liver disease is not an isolated condition. It fits into a broader context of metabolic dysfunctions affecting multiple organs. Early detection and appropriate management could therefore not only preserve liver health but also prevent serious kidney complications.<\/p>\n
DOI:<\/strong> https:\/\/doi.org\/10.1007\/s11154-026-10059-0<\/a><\/p>\n Title:<\/strong> Association between metabolic dysfunction-associated steatotic liver disease\/non-alcoholic fatty liver disease and chronic kidney disease: a systematic review and meta-analysis<\/p>\n Journal:<\/strong> Reviews in Endocrine and Metabolic Disorders<\/p>\n Publisher:<\/strong> Springer Science and Business Media LLC<\/p>\n Authors:<\/strong> Andr\u00e9 O. Soares; Davi A. C. Loli; Gustavo R. Carvalho; Vinicius Daher Alvares Delfino; Paulo Roberto Bignardi<\/p>\n","protected":false},"excerpt":{"rendered":" Metabolic fatty liver disease increases the risk of chronic kidney disease A close relationship links metabolic fatty liver disease to chronic kidney disease. This liver condition, formerly known as non-alcoholic fatty liver disease, now affects nearly one-third of adults worldwide. It is characterized by an abnormal accumulation of fat in the liver, often associated with… Continue reading Metabolic fatty liver disease increases the risk of chronic kidney disease<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2,4,8],"tags":[],"class_list":["post-71","post","type-post","status-publish","format-standard","hentry","category-health","category-human-humanitarian","category-society","entry"],"_links":{"self":[{"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/posts\/71","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/comments?post=71"}],"version-history":[{"count":1,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/posts\/71\/revisions"}],"predecessor-version":[{"id":72,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/posts\/71\/revisions\/72"}],"wp:attachment":[{"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/media?parent=71"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/categories?post=71"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/tags?post=71"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}